| 17.63 0.16 (0.92%) | 12-31 19:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 20.68 | 1-year : | 24.16 |
| Resists | First : | 17.7 | Second : | 20.68 |
| Pivot price | 17.62 | |||
| Supports | First : | 17.49 | Second : | 17.36 |
| MAs | MA(5) : | 17.62 | MA(20) : | 17.62 |
| MA(100) : | 17.62 | MA(250) : | 17.97  |
|
| MACD | MACD : | -0.1  |
Signal : | -0.1 |
| %K %D | K(14,3) : | 77.1 | D(3) : | 77.1 |
| RSI | RSI(14): 49.3 | |||
| 52-week | High : | 21.52 | Low : | 16.04 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ OCDX ] has closed Bollinger Bands are 0% narrower than normal.
| If tomorrow: | Open lower | Open higher |
| High: | 17.75 - 17.84 | 17.84 - 17.91 |
| Low: | 17.12 - 17.24 | 17.24 - 17.33 |
| Close: | 17.46 - 17.64 | 17.64 - 17.79 |
Ortho Clinical Diagnostics Holdings plc provides in-vitro diagnostics solutions to the clinical laboratory and transfusion medicine communities worldwide. The company offers automated instruments; and assays, reagents, and other consumables that are used by these instruments to generate test results. Its solutions include clinical chemistry and immunoassay instruments and tests to detect and monitor disease progression across a spectrum of therapeutic areas, including COVID-19 antibody and antigen tests; and immunohematology instruments and tests for blood typing to ensure patient-donor compatibility in blood transfusions, as well as donor screening instruments and tests for blood and plasma screening for infectious diseases. The company is also involved in the provision of contract manufacturing and orthocare services. Its products are used in hospitals, laboratories, clinics, blood banks, and donor centers. Ortho Clinical Diagnostics Holdings plc was founded in 1939 and is headquartered in Raritan, New Jersey.
Wed, 30 Aug 2023
Why Natera Inc's Stock Skyrocketed 21% in a Quarter: A Deep Dive - GuruFocus.com
Wed, 10 May 2023
J&J completes $4 billion OCD sale - Pharmafile
Fri, 27 May 2022
Quidel, Ortho Clinical Diagnostics combine to form in vitro diagnostics company - Mass Device
Thu, 26 May 2022
Quidel and Ortho Announce Expected Closing of Ortho Transaction - Business Wire
Tue, 28 Dec 2021
Quidel Corporation Acquires Ortho Clinical Diagnostics for $6B - HIT Consultant
Thu, 23 Dec 2021
Quidel to Acquire Ortho Clinical Diagnostics for $6 Billion - Bloomberg
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Outperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Diagnostics & Research
|
|
| Shares Out | 238 (M) |
| Shares Float | 119 (M) |
| Held by Insiders | 0.3 (%) |
| Held by Institutions | 98.3 (%) |
| Shares Short | 7,020 (K) |
| Shares Short P.Month | 6,800 (K) |
| EPS | -0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.87 |
| Profit Margin | -0.1 % |
| Operating Margin | 8.4 % |
| Return on Assets (ttm) | 3.2 % |
| Return on Equity (ttm) | -0.2 % |
| Qtrly Rev. Growth | -1.3 % |
| Gross Profit (p.s.) | 4.37 |
| Sales Per Share | 8.58 |
| EBITDA (p.s.) | 1.89 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 293 (M) |
| Levered Free Cash Flow | 400 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0.4 |
| Price to Book value | 9.42 |
| Price to Sales | 2.05 |
| Price to Cash Flow | 14.32 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|